Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRD-002
- Development stage
- Preclinical
- Lead developer
- Sardocor
- Modality
- Small Molecules
- Administration
- Intracoronary Infusion
01
Overview
SRD-002 is a small molecule activator of the sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a) being developed by Sardocor for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). SERCA2a is a calcium pump that plays a vital role in cardiomyocyte relaxation by sequestering calcium into the sarcoplasmic reticulum during diastole. Impaired SERCA2a activity is a hallmark of heart failure, leading to poor calcium handling and diastolic dysfunction. By enhancing SERCA2a function, SRD-002 aims to improve cardiac relaxation and overall heart function in patients with HFpEF. The program is currently in the preclinical stage of development.
02
Targets
SERCA2
Beyond the preview
Go deeper on SRD-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRD-002.